Indexado en

Licencia y uso

Citaciones

Cited 8 times in

Cited 8 times in

Altmetrics

Grant support

The study was supported by Fondo de Investigaciones Sanitarias (FIS-EC07/90466) of Instituto de Salud Carlos III, Madrid, Spain and by Fundacion Teofilo Hernando, a non-profit foundation linked to Universidad Autonoma de Madrid. The authors have no other relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript apart from those disclosed.

Análisis de autorías institucional

Compartir

Pharmacodynamic genetic variants related to antipsychotic adverse reactions in healthy volunteers

Publicado en:Pharmacogenomics. 14 (10): 1203-1214 - 2013-07-01 14(10), DOI: 10.2217/PGS.13.106

Autores: Lopez-Rodriguez, Rosario; Cabaleiro, Teresa; Ochoa, Dolores; Roman, Manuel; Borobia, Alberto M; Carcas, Antonio J; Ayuso, Carmen; Novalbos, Jesus; Abad-Santos, Francisco

Afiliaciones

Resumen

Aim: Clinical trials with healthy volunteers are a useful model for evaluating safety and tolerability, without the interference of concomitant diseases and drugs. The present study aims to improve our understanding of antipsychotic-related adverse reactions (ARs) and their possible association with common genetic variants of pharmacodynamic proteins such as neurotransmitter receptors/transporters. Materials & methods: A total of eight polymorphisms located in seven pharmacodynamic-related genes (SCL6A4, MDR1, 5HT2A, DRD2, DRD3, COMT and GRIN2B) were genotyped in a cohort of 211 healthy volunteers who received a single dose of risperidone (1 mg), olanzapine (5 mg) or quetiapine (25 mg). Results: Interestingly, a significant association was found between the incidence of neurological ARs and specific polymorphisms in key genes (DRD2 and SCL6A4). Conclusion: Genetic variants in pharmacodynamic genes could represent valuable markers of AR risk and antipsychotic safety.

Palabras clave